OpenURL Connection Search

Select item for more details and to access through your institution.

Publisher Correction: Co-targeting CDK4/6 and AKT with endocrine therapy prevents progression in CDK4/6 inhibitor and endocrine therapy-resistant breast cancer.
Published in:
2021
By:
- Alves, Carla L.;
- Ehmsen, Sidse;
- Terp, Mikkel G.;
- Portman, Neil;
- Tuttolomondo, Martina;
- Gammelgaard, Odd L.;
- Hundebøl, Monique F.;
- Kaminska, Kamila;
- Johansen, Lene E.;
- Bak, Martin;
- Honeth, Gabriella;
- Bosch, Ana;
- Lim, Elgene;
- Ditzel, Henrik J.
Publication type:
Correction Notice
Co-targeting CDK4/6 and AKT with endocrine therapy prevents progression in CDK4/6 inhibitor and endocrine therapy-resistant breast cancer.
Published in:
Nature Communications, 2021, v. 12, n. 1, p. 1, doi. 10.1038/s41467-021-25422-9
By:
- Alves, Carla L.;
- Ehmsen, Sidse;
- Terp, Mikkel G.;
- Portman, Neil;
- Tuttolomondo, Martina;
- Gammelgaard, Odd L.;
- Hundebøl, Monique F.;
- Kaminska, Kamila;
- Johansen, Lene E.;
- Bak, Martin;
- Honeth, Gabriella;
- Bosch, Ana;
- Lim, Elgene;
- Ditzel, Henrik J.
Publication type:
Article
Co-targeting CDK4/6 and AKT with endocrine therapy prevents progression in CDK4/6 inhibitor and endocrine therapy-resistant breast cancer.
Published in:
Nature Communications, 2021, v. 12, n. 1, p. 1, doi. 10.1038/s41467-021-25422-9
By:
- Alves, Carla L.;
- Ehmsen, Sidse;
- Terp, Mikkel G.;
- Portman, Neil;
- Tuttolomondo, Martina;
- Gammelgaard, Odd L.;
- Hundebøl, Monique F.;
- Kaminska, Kamila;
- Johansen, Lene E.;
- Bak, Martin;
- Honeth, Gabriella;
- Bosch, Ana;
- Lim, Elgene;
- Ditzel, Henrik J.
Publication type:
Article
MCM3 upregulation confers endocrine resistance in breast cancer and is a predictive marker of diminished tamoxifen benefit.
Published in:
NPJ Breast Cancer, 2021, v. 7, n. 1, p. 1, doi. 10.1038/s41523-020-00210-8
By:
- Løkkegaard, Sanne;
- Elias, Daniel;
- Alves, Carla L.;
- Bennetzen, Martin V.;
- Lænkholm, Anne-Vibeke;
- Bak, Martin;
- Gjerstorff, Morten F.;
- Johansen, Lene E.;
- Vever, Henriette;
- Bjerre, Christina;
- Kirkegaard, Tove;
- Nordenskjöld, Bo;
- Fornander, Tommy;
- Stål, Olle;
- Lindström, Linda S.;
- Esserman, Laura J.;
- Lykkesfeldt, Anne E.;
- Andersen, Jens S.;
- Leth-Larsen, Rikke;
- Ditzel, Henrik J.
Publication type:
Article
Co-targeting CDK2 and CDK4/6 overcomes resistance to aromatase and CDK4/6 inhibitors in ER+ breast cancer.
Published in:
NPJ Precision Oncology, 2022, v. 6, n. 1, p. 1, doi. 10.1038/s41698-022-00311-6
By:
- Al-Qasem, Abeer J.;
- Alves, Carla L.;
- Ehmsen, Sidse;
- Tuttolomondo, Martina;
- Terp, Mikkel G.;
- Johansen, Lene E.;
- Vever, Henriette;
- Hoeg, Luna V. A.;
- Elias, Daniel;
- Bak, Martin;
- Ditzel, Henrik J.
Publication type:
Article
Triple combination targeting PI3K, ER, and CDK4/6 inhibits growth of ER‐positive breast cancer resistant to fulvestrant and CDK4/6 or PI3K inhibitor.
Published in:
Cancer Communications, 2023, v. 43, n. 6, p. 720, doi. 10.1002/cac2.12425
By:
- Karimi, Leena;
- Alves, Carla L.;
- Terp, Mikkel G.;
- Tuttolomondo, Martina;
- Portman, Neil;
- Ehmsen, Sidse;
- Johansen, Lene E.;
- Bak, Martin;
- Lim, Elgene;
- Ditzel, Henrik J.
Publication type:
Article

Found: 6

Publisher Correction: Co-targeting CDK4/6 and AKT with endocrine therapy prevents progression in CDK4/6 inhibitor and endocrine therapy-resistant breast cancer.

Co-targeting CDK4/6 and AKT with endocrine therapy prevents progression in CDK4/6 inhibitor and endocrine therapy-resistant breast cancer.

Co-targeting CDK4/6 and AKT with endocrine therapy prevents progression in CDK4/6 inhibitor and endocrine therapy-resistant breast cancer.

MCM3 upregulation confers endocrine resistance in breast cancer and is a predictive marker of diminished tamoxifen benefit.

Co-targeting CDK2 and CDK4/6 overcomes resistance to aromatase and CDK4/6 inhibitors in ER+ breast cancer.

Triple combination targeting PI3K, ER, and CDK4/6 inhibits growth of ER‐positive breast cancer resistant to fulvestrant and CDK4/6 or PI3K inhibitor.